Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

Gut

Volumn 44, Issue 5, 1999, Pages 682-686

  Bouras, E P ^a   Camilleri, M ^a   Burton, D D ^a   McKinzie, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Benzofuran; Colon; Gastrointestinal; Motility; Prucalopride; Transit

Indexed keywords

PRUCALOPRIDE; SEROTONIN 4 AGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; GEOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTESTINE MOTILITY; INTESTINE SECRETION; INTESTINE TRANSIT TIME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE;

EID: 0033005188     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.682     Document Type: Article

References (39)

1. 1 Briejer MR, Meulemans AL, Bosmans J-P, et al. In vitro pharmacology of the novel enterokinetic R093877 [abstract]. Gastroenterology 1997;112:A705.
2. 2 Briejer MR, Ghoos E, Eelen J, Schuurkes JAJ. Serotonin 5HT, receptors mediate the R093877-induced changes in contractile patterns in the canine colon [abstract]. Gastroenterology 1997;112:A705.
3. 3 Investigator's Brochure on R093877. Janssen Pharmaceutica, November 1997.
4. 4 Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982;83:529-34.
5. 5 Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38: 1569-80.
6. 6 Talley NJ, Weaver AL, Zinsmeister AR, et al. Functional constipation and outlet delay: a population-based study. Gastroenterology 1993;105:781-90.
7. 7 Kuijpers HC. Application of the colorectal laboratory in diagnosis and treatment of functional constipation. Dis Colon Rectum 1990;33:35-9.
8. 8 Surrenti E, Rath DM, Pemberton JH, et al. Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol 1995;90:1471-5.
9. 9 Reynolds JC, Ouyang A, Lee CA, et al. Chronic severe constipation. Prospective motility studies in 25 consecutive patients. Gastroenterology 1987;92:414-20.
10. 10 Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991;101:107-15.
11. 11 van der Sijp JR, Kamm MA, Nightingale JM, et al. Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers. Gut 1993;34:402-8.
12. 12 Gattuso JM, Kamm MA, Morris G, et al. Gastrointestinal transit in patients with idiopathic megarectum. Dis Colon Rectum 1996;39:1044-50.
13. 13 Gardner VY, Beckwith JV, Heyneman CA. Cisapride for the treatment of chronic idiopathic constipation. Ann Pharmacother 1995;29:1161-3.
14. 14 Muller-Lissner SA and the Bavarian Constipation Study Group. Cisapride in chronic idiopathic constipation: can the colon be re-educated? Eur J Gastroenterol Hepatol 1995; 7:69-73.
15. 15 Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord 1993;8:339-43.
16. 16 Geders JM, Gaing A, Bauman WA, et al. The effect of cisapride on segmental colonic transit time in patients with spinal cord injury. Am J Gastroenterol 1995;90:285-9.
17. 17 Bazzocchi G, Ellis J, Villanueva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990;98:686-93.
18. 18 O'Brien MD, Camilleri M, von der Ohe MR, et al. Motility and tone of the left colon in constipation: a role in clinical practice? Am J Gastroenterol 1996;91:2532-8.
19. 19 Pemberton JH, Rath DM, Ilstrup DM. Evaluation and surgical treatment of severe chronic constipation. Ann Surg 1991;214:403-11.
20. 20 Talley NJ, Phillips SF, Melton LJ III, et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989;111:671-4.
21. 21 Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989;257:G284-90.
22. 22 Proano M, Camilleri M, Phillips SF, et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990;258:G856-62.
23. 23 Camilleri M, Zinsmeister AR, Greydanus MP, et al. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991;36:609-15.
24. 24 Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992;103:36-42.
25. 25 Burton DD, Camilleri M, Mullan BP, et al. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997;38:1807-10.
26. 26 Camilleri M, Brown ML, Malagelada J-R. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986;91:619-26.
27. 27 Madsen JL. Effects of cisapride on gastrointestinal transit in healthy humans. Dig Dis Sci 1990;35:1500-4.
28. 28 Fraser R, Horowitz M, Maddox A, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993;264:G195-201.
29. 29 Duan LP, Braden B, Caspary WF, et al. Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests. Dig Dis Sci 1995;40:2200-6.
30. 30 Annese V, Lombardi G, Frusciante V, et al. Cisapride and erythromycin prokinetic effects in gastroparesis due to type I (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997;11:599-603.
31. 31 Krevsky B, Malmud LS, Maurer AH, et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 4:293-304.
32. 32 Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-16.
33. 33 Briejer MR, Van Daele P, Bosmans J-P, et al. Dose-dependent effects after oral and intravenous administration of R093877 on colonic motility in conscious dogs [abstract]. Gastroenterology 1997;112:A704.
34. 34 Prins NH, Briejer MR, Schuurkes JA. Characterization of the contraction to 5-HT in the canine colon longitudinal muscle. Br J Pharmacol 1997;120:714-20.
35. 35 Grady EF, Bohm SK, Bunnett NW. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 1997;273:G586-601.
36. 36 Baez M, Kursar JD, Helton LA, et al. Molecular biology of serotonin receptors. Obes Res 1995;3:441S-7S.
37. 37 Briejer MR, Meulemans AL, Welles A, et al. R093877 dose-dependently accelerates delayed gastric emptying in conscious dogs [abstract]. Gastroenterology 1997;112:A705.
38. 38 Edwards CA, Holden S, Brown C, et al. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut 1987;28:13-16.
39. 39 Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47 116-52.